COMPASS Pathways Toekomstige groei
Future criteriumcontroles 0/6
COMPASS Pathways zal naar verwachting groeien in winst en omzet met respectievelijk 23.6% en 85.2% per jaar. De winst per aandeel zal naar verwachting groeien met 29.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -132.1% zijn.
Belangrijke informatie
23.6%
Groei van de winst
29.1%
Groei van de winst per aandeel
Biotechs winstgroei | 28.0% |
Inkomstengroei | 85.2% |
Toekomstig rendement op eigen vermogen | -132.1% |
Dekking van analisten | Good |
Laatst bijgewerkt | 01 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Compass Pathways: Minor Delay Of COMP360 Data Brings About Buy Opportunity
Nov 01Compass Pathways: Sector-Wide Reality Check Needed Post FDA Lykos MDMA Decision
Aug 19Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies
Jul 08Psychedelics Closer To Commercialization; Compass Far And Away The Leader
May 23COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way Or Slam The Door Shut?
Apr 25Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Feb 08Companies Like COMPASS Pathways (NASDAQ:CMPS) Are In A Position To Invest In Growth
Dec 06Booker again pushes for easier access to psychedelics for terminally ill patients
Oct 19Here's Why We're Not Too Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Situation
Aug 13COMPASS Pathways And The Trillion Dollar Opportunity
Aug 11COMPASS Pathways ADS Q2 2022 Earnings Preview
Aug 03COMPASS Pathways names new CEO
Jul 19Compass Pathways: Shares Look Cheap But Proving Psilocybin Case Won't Be Easy
Jun 30We're Hopeful That COMPASS Pathways (NASDAQ:CMPS) Will Use Its Cash Wisely
Apr 28Checking In On Compass Pathways
Mar 02We Think COMPASS Pathways (NASDAQ:CMPS) Can Afford To Drive Business Growth
Dec 29Compass Pathways: Psychedelics For Mental Health
Nov 23Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy
Sep 17COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
Sep 15Compass Pathways: Huge Growth Potential, But I'm Cautious
Jun 04COMPASS Pathways (NASDAQ:CMPS) Is In A Good Position To Deliver On Growth Plans
May 25COMPASS Pathways raises $144M capital via equity offering
Apr 30COMPASS Pathways launches public offering
Apr 27We're Not Very Worried About COMPASS Pathways' (NASDAQ:CMPS) Cash Burn Rate
Feb 08Psilocybin Will Change Mental Health, Compass Pathways Could Be At The Forefront
Jan 01Compass Pathways: Risky And Overvalued
Dec 18What Type Of Shareholders Make Up COMPASS Pathways plc's (NASDAQ:CMPS) Share Registry?
Dec 18Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 9 | -187 | -183 | -177 | 6 |
12/31/2025 | N/A | -155 | -137 | -135 | 7 |
12/31/2024 | N/A | -157 | -120 | -120 | 8 |
9/30/2024 | N/A | -144 | -105 | -105 | N/A |
6/30/2024 | N/A | -139 | -100 | -100 | N/A |
3/31/2024 | N/A | -129 | -91 | -90 | N/A |
12/31/2023 | N/A | -118 | -97 | -97 | N/A |
9/30/2023 | N/A | -117 | -115 | -115 | N/A |
6/30/2023 | N/A | -102 | -117 | -117 | N/A |
3/31/2023 | N/A | -95 | -111 | -110 | N/A |
12/31/2022 | N/A | -92 | -106 | -105 | N/A |
9/30/2022 | N/A | -86 | -83 | -83 | N/A |
6/30/2022 | N/A | -84 | -78 | -77 | N/A |
3/31/2022 | N/A | -80 | -77 | -77 | N/A |
12/31/2021 | N/A | -72 | -68 | -68 | N/A |
9/30/2021 | N/A | -65 | -62 | -62 | N/A |
6/30/2021 | N/A | -66 | -62 | -62 | N/A |
3/31/2021 | N/A | -64 | -51 | -51 | N/A |
12/31/2020 | N/A | -60 | -42 | -41 | N/A |
9/30/2020 | N/A | -49 | -31 | -31 | N/A |
6/30/2020 | N/A | -38 | -22 | -22 | N/A |
3/31/2020 | N/A | -25 | -19 | -19 | N/A |
12/31/2019 | N/A | -20 | -18 | -18 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat CMPS de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat CMPS de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat CMPS de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: Er wordt verwacht dat CMPS volgend jaar geen omzet zal hebben.
Hoge groei-inkomsten: Er wordt verwacht dat CMPS volgend jaar geen omzet zal hebben.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat CMPS binnen 3 jaar verliesgevend zal zijn.